AMG0103 rescues spinal discs in preliminary drug trial

• Jun 27, 2025 • by Paul Ingraham
Get posts in your inbox:

A weekly nugget or two of pain science news and ideas for patients and pros, usually 400–1000 words. The blog is the “director’s commentary” on the core content of PainScience.com: a library of major articles and books about common painful problems and popular treatments. See the blog archives or updates for the whole site.

Two anatomical illustrations of a lumbar intervertebral disc show the target site for a therapeutic injection. The top image is an axial (top-down) view of the disc between vertebrae, with a red bullseye target centered in the nucleus pulposus and a blue dart embedded in it. The bottom image is a sagittal (side) cross-section showing the same target-and-dart motif within the disc. The images symbolize the precise delivery of an intradiscal injection of AMG0103 directly into the center of a degenerated spinal disc.

AMG0103 targets very specific anatomy (the nucleus pulposus of an intervertebral disc) and very specific physiology: it interferes with inflammatory degeneration of tissues in an intervertebral disc.

A small new study is a big (early) win for a new kind of medication for back pain (and probably more). For now, it’s known as “AMG0103,” a working title for this mouthful of a molecule, which is an NF-kappa B oligonucleotide decoy. Its goal is to suppress inflammation-powered tissue degeneration in spinal discs by interfering with an immune system pathway further “upstream” than other anti-inflammatory drugs: “a therapy that simultaneously targets specific actions of multiple key cytokines,” by acting “as a decoy for the NF-kB DNA binding sequence in the disc.”

In other words, AMG0103 is not just a pain blocker, but a pain solver that meaningfully reduces the excessively persistent and destructive inflammation that may be the root of many painful problems — or at least closer to the root. Not all inflammation is functional! To test this principle, the researchers gave an intradiscal injection of AMG0103 to 25 patients with presumed discogenic low back pain, right into the gooey nucleus of degenerated spinal discs …

I’ve moved the bulk of this post behind a paywall, as a part of my low back pain book, and only accessible to owners of that specific book (and not even members, unless they’ve bought that book). The audio version remains available to members. The whole post was free for all readers for about 8 months.